Drug intelligence / Profile preview

Era-107

Development stage: Unknown
Lead developer: Novo Nordisk

Overview

Era-107 is a lead compound developed by EraCal Therapeutics, a spinout from Harvard and the University of Zurich. It is an appetite suppressant primarily indicated for obesity. The drug was discovered using EraCal's zebrafish-based phenotypic drug discovery platform and was gearing up for first-in-human trials. Novo Nordisk has partnered with EraCal Therapeutics to identify novel drug targets for obesity, leveraging EraCal's platform to expand Novo Nordisk's obesity pipeline.

Beyond the preview

Go deeper on Era-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Era-107.

Explore the full profile